Osimertinib for compound EGFR exon 19 deletion/T790M mutated lung squamous cell carcinoma

Lignende værker

• Association of EGFR Exon 19 Deletion and EGFR-TKI Treatment Duration with Frequency of T790M Mutation in EGFR-Mutant Lung Cancer Patients
  af: Matsuo, Norikazu, et al.
  Udgivet: (2016)
• Osimertinib-Induced Hepatitis Following Immunotherapy in a Patient with Lung Adenocarcinoma Harboring De Novo EGFR Exon 19 Deletion and T790M Mutations: A Case Report
  af: Bradley Steiner, et al.
  Udgivet: (2025-06-01)
• Osimertinib for advanced non-small cell lung cancer harboring EGFR mutation exon 20 T790M, acquired resistant mutation for first- or second-generation EGFR-TKI
  af: Okuma, Yusuke, et al.
  Udgivet: (2017)
• Case report: primary resistance to osimertinib in erlotinib-pretreated lung adenocarcinoma with EGFR T790 M mutation
  af: Zheng, Lin-Peng, et al.
  Udgivet: (2018)
• Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
  af: Mok, T.S., et al.
  Udgivet: (2016)